Navigation

Alti-Bromocriptine

Alti-Bromocriptine - General Information

A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.

 

Pharmacology of Alti-Bromocriptine

Alti-Bromocriptine is an ergoline derivitave dopamine agonist that is used in the treatment of amenorrhea, female infertility, abnormal discharge of breast milk, hypogonadism, Parkinson's disease, and acromegaly. Alti-Bromocriptine produces its therapeutic effect in the treatment of Parkinson's disease, a clinical condition characterized by a progressive deficiency in dopamine synthesis in the substantia nigra, by directly stimulating the dopamine receptors in the corpus striatum.

 

Alti-Bromocriptine for patients

During clinical trials, dizziness (8%-16%), drowsiness (8%), faintness, fainting (8%), and syncope (less than 1%) have been reported early in the course of Parlodel therapy. In post-marketing reports, Parlodel has been associated with somnolence, and episodes of sudden sleep onset, particularly in patients with Parkinsonís disease. Sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported very rarely. All patients receiving Parlodel should be cautioned with regard to engaging in activities requiring rapid and precise responses, such as driving an automobile or operating machinery.

Patients receiving Parlodel for hyperprolactinemic states associated with macroadenoma or those who have had previous transsphenoidal surgery, should be told to report any persistent watery nasal discharge to their physician. Patients receiving Parlodel for treatment of a macroadenoma should be told that discontinuation of drug may be associated with rapid regrowth of the tumor and recurrence of their original symptoms.

 

Alti-Bromocriptine Interactions

The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate. Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents. Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide. Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.

 

Alti-Bromocriptine Contraindications

Uncontrolled hypertension and sensitivity to any ergot alkaloids. In patients being treated for hyperprolactinemia bromocriptine mesylate should be withdrawn when pregnancy is diagnosed. In the event that bromocriptine mesylate is reinstituted to control a rapidly expanding macroadenoma and a patient experiences a hypertensive disorder of pregnancy, the benefit of continuing bromocriptine mesylate must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy. When bromocriptine mesylate is being used to treat acromegaly, prolactinoma, or Parkinsonís disease in patients who subsequently become pregnant, a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn. If it is continued, the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of bromocriptine mesylate is considered to be medically contraindicated. The drug should not be used during the post-partum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated. If the drug is used in the post-partum period the patient should be observed with caution.

 

Additional information about Alti-Bromocriptine

Alti-Bromocriptine Indication: For treatment of idiopathic or postencephalitic Parkinson's disease, dysfunctions associated with hyperprolactinemia and in the treatment of acromegaly.
Mechanism Of Action: Alti-Bromocriptine acts by directly stimulating the dopamine receptors in the corpus striatum.
Drug Interactions: Acetophenazine The phenothiazine decreases the effect of bromocriptine
Chlorpromazine The phenothiazine decreases the effect of bromocriptine
Ethopropazine The phenothiazine decreases the effect of bromocriptine
Fluphenazine The phenothiazine decreases the effect of bromocriptine
Mesoridazine The phenothiazine decreases the effect of bromocriptine
Methdilazine The phenothiazine decreases the effect of bromocriptine
Perphenazine The phenothiazine decreases the effect of bromocriptine
Prochlorperazine The phenothiazine decreases the effect of bromocriptine
Promazine The phenothiazine decreases the effect of bromocriptine
Promethazine The phenothiazine decreases the effect of bromocriptine
Propiomazine The phenothiazine decreases the effect of bromocriptine
Thiethylperazine The phenothiazine decreases the effect of bromocriptine
Thioridazine The phenothiazine decreases the effect of bromocriptine
Trifluoperazine The phenothiazine decreases the effect of bromocriptine
Triflupromazine The phenothiazine decreases the effect of bromocriptine
Trimeprazine The phenothiazine decreases the effect of bromocriptine
Erythromycin Erythromycin increases serum levels of bromocriptine
Josamycin Erythromycin increases serum levels of bromocriptine
Phenylpropanolamine The sympathomimetic increases the toxicity of bromocriptine
Pseudoephedrine The sympathomimetic increases the toxicity of bromocriptine
Methotrimeprazine The phenothiazine decreases the effect of bromocriptine
Food Interactions: Avoid alcohol.
Take with food to reduce irritation.
Generic Name: Bromocriptine
Synonyms: Bromocriptina [Inn-Spanish]; Bromocriptin; Bromergocryptine; Bromocriptine Mesylate; Bromocriptine Methanesulfonate; Bromocriptinum [Inn-Latin]; Bromocryptine; Bromocryptine Mesylate; Bromoergocriptine; Bromoergocryptine
Drug Category: Antiparkinson Agents; Antidyskinetics
Drug Type: Small Molecule; Approved
Other Brand Names containing Bromocriptine: Alti-Bromocriptine; Apo-Bromocriptine; Parlodel; Parlodel Snaptabs; Pravidel; Bagren;
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: 90-96%
Biotransformation: Not Available
Half Life: 4-15 hours
Dosage Forms of Alti-Bromocriptine: Tablet Oral
Capsule Oral
Chemical IUPAC Name: Not Available
Chemical Formula: C32H40BrN5O5
Bromocriptine on Wikipedia: http://en.wikipedia.org/wiki/Bromocriptine
Organisms Affected: Humans and other mammals